Endobronchial photodynamic therapy for lung cancer

Loewen, Gregory; Pandey, Ravindra K.; Bellnier, David A.; Henderson, Barbara W.; Dougherty, Thomas J.

doi:10.1002/lsm.20354

Cited by 83 publications

(60 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our experiments, we varied light rather than photosensitizer dose because the lack of drug-light reciprocity due to sensitizer photobleaching can cause artifacts at low photosensitizer concentrations (29) and also because clinically, a fixed dose of the photosensitizer is given, whereas the physician can alter the light dose. Because HPPH is a derivative of pyropheophorbide-a, the results for this agent, which is in promising phase II trials (30,31), are consistent with the recent report of Robey et al that pyropheophorbide-a is a substrate of ABCG2 (8). As shown in Fig.…”

Section: Discussionsupporting

confidence: 88%

The Tyrosine Kinase Inhibitor Imatinib Mesylate Enhances the Efficacy of Photodynamic Therapy by Inhibiting ABCG2

Liu¹,

Baer

Bowman³

et al. 2007

Clinical Cancer Research

131

134

View full text Add to dashboard Cite

Purpose: The ATP-binding cassette protein ABCG2 (breast cancer resistance protein) effluxes some of the photosensitizers used in photodynamic therapy (PDT) and, thus, may confer resistance to this treatment modality. Tyrosine kinase inhibitors (TKI) can block the function of ABCG2. Therefore, we tested the effects of the TKI imatinib mesylate (Gleevec) on photosensitizer accumulation and in vitro and in vivo PDTefficacy. Experimental Design: Energy-dependent photosensitizer efflux and imatinib mesylate's effects on intracellular accumulation of clinically used second-and first-generation photosensitizers were studied by flow cytometry in murine and human cells with and without ABCG2 expression. Effects of ABCG2 inhibition on PDT were examined in vitro using cell viability assays and in vivo measuring photosensitizer accumulation and time to regrowth in a RIF-1tumor model. Results: Energy-dependent efflux of 2-(1-hexyloxethyl)-2-devinyl pyropheophorbide-a (HPPH, Photochlor), endogenous protoporphyrin IX (PpIX) synthesized from 5-aminolevulenic acid, and the benzoporphyrin derivative monoacid ring A (BPD-MA, Verteporfin) was shown in ABCG2+ cell lines, but the first-generation multimeric photosensitizer porfimer sodium (Photofrin) and a novel derivative of HPPH conjugated to galactose were minimally transported. Imatinib mesylate increased accumulation of HPPH, PpIX, and BPD-MA from 1.3-to 6-fold in ABCG2+ cells, but not in ABCG2À cells, and enhanced PDTefficacy both in vitro and in vivo. Conclusions: Second-generation clinical photosensitizers are transported out of cells by ABCG2, and this effect can be abrogated by coadministration of imatinib mesylate. By increasing intracellular photosensitizer levels in ABCG2+ tumors, imatinib mesylate or other ABCG2 transport inhibitors may enhance efficacy and selectivity of clinical PDT.Photodynamic therapy (PDT) is used for the treatment of many cancers. Photosensitizers are taken up by tumor cells and then activated by light (1), generating reactive oxygen species that cause cell death by necrosis or apoptosis (2). Expression of ATP-binding cassette (ABC) transport proteins renders tumor cells resistant to chemotherapy drugs that are substrates of these proteins (3), and the effect of these transporters on intracellular photosensitizer accumulation has been examined as a potential cause of resistance to PDT. The ABC family transport protein that has been most thoroughly investigated is ABCB1, or P-glycoprotein, but photosensitizers were found not to be substrates for this pump (4 -8), nor were they substrates for ABCC1, or multidrug resistance-associated protein-1 (8). In contrast, another ABC family transport protein, ABCG2 or breast cancer resistance protein, has been found to transport some photosensitizers and to decrease intracellular photosensitizer accumulation (8). Jonker et al. (9) showed that ABCG2 knock-out mice were photosensitive because of increased protoporphyrin IX (PpIX) levels. Robey et al. found that pheophorbide a is a specific substrate for...

show abstract

Section: Discussionsupporting

confidence: 88%

The Tyrosine Kinase Inhibitor Imatinib Mesylate Enhances the Efficacy of Photodynamic Therapy by Inhibiting ABCG2

Liu¹,

Baer

Bowman³

et al. 2007

Clinical Cancer Research

131

134

View full text Add to dashboard Cite

show abstract

“…DNA microarray analysis indicated the absence of ATDC expression in prostate cancers on the basis of mRNA expression level (Ernst et al, 2002). So far, results of several expression analyses of TRIM29 using human normal and cancer tissues have been reported with TRIM29 being highly expressed in the lung, bladder, colorectal, ovarian, endometrial cancers and multiple myeloma (Dyrskjot et al, 2004;Glebov et al, 2006;Hawthorn et al, 2006;Loewen et al, 2006;Mutter et al, 2001;Santin et al, 2004;Zhan et al, 2002). Previous analyses also suggested that TRIM29 is involved in the response to DNA damage through p53 and functions as an oncogene that promotes tumorigenesis (Sho et al, 2011;Yuan et al, 2010).…”

Section: Discussionmentioning

confidence: 99%

TRIM29 as a novel prostate basal cell marker for diagnosis of prostate cancer

et al. 2014

View full text Add to dashboard Cite

Tripartite motif protein 29 (TRIM29) is one of the TRIM family proteins, some of which function as E3 ubiquitin ligases. In this study, we investigated the usefulness of TRIM29 for diagnosis of prostate cancer. Prostate tissues including carcinoma and non-carcinoma tissues obtained by needle biopsy and radical prostatectomy were used.Immunohistochemistry was performed according to standard procedures using an antibody against TRIM29. Immunohistochemical staining with an antibody against 34βE12, which recognizes cytokeratins 1, 5, 10 and 14, was performed as a control.Basal cells of normal prostatic glands were stained with anti-TRIM29 antibody in all cases, whereas prostate cancer tissues had no or little staining with anti-TRIM29 antibody. TRIM29 is selectively expressed in basal cells of the normal prostate gland, and immunohistochemical staining with anti-TRIM29 antibody showed the same expression pattern as that with 34βE12 in prostate cancer and its benign mimics. Our data indicate that TRIM29 may be useful for distinguishing prostate cancers from benign tissues.

show abstract

“…25,26 Simulations performed at 670 nm were chosen to correspond to the absorption of photosensitizers such as HPPH or methylene blue. HPPH has been used in the treatment of thoracic malignancies, 27,28 Barrett's esophagus, 29 and early cancers and precancers of the oral cavity. 30 Methylene blue is FDA-approved as a diagnostic dye and is the only known treatment for methemoglobinemia.…”

Section: Discussionmentioning

confidence: 99%

Optical property measurements establish the feasibility of photodynamic therapy as a minimally invasive intervention for tumors of the kidney

et al. 2012

View full text Add to dashboard Cite

Abstract. We measured the optical properties of freshly excised kidneys with renal parenchymal tumors to assess the feasibility of photodynamic therapy (PDT) in these patients. Kidneys were collected from 16 patients during surgical nephrectomies. Spatially resolved, white light, steady-state diffuse reflectance measurements were performed on normal and neoplastic tissue identified by a pathologist. Reflectance data were fit using a radiative transport model to obtain absorption (μ a ) and transport scattering coefficients (μ 0 s ), which define a characteristic light propagation distance, δ. Monte Carlo (MC) simulations of light propagation from cylindrical diffusing fibers were run using the optical properties extracted from each of the kidneys. Interpretable spectra were obtained from 14 kidneys. Optical properties of human renal cancers exhibit significant inter-lesion heterogeneity. For all diagnoses, however, there is a trend toward increased light penetration at longer wavelengths. For renal cell carcinomas (RCC), mean values of δ increase from 1.28 to 2.78 mm as the PDT treatment wavelength is increased from 630 to 780 nm. MC simulations of light propagation from interstitial optical fibers show that fluence distribution in tumors is significantly improved at 780 versus 630 nm. Our results support the feasibility of PDT in selected renal cancer patients, especially with photosensitizers activated at longer wavelengths.

show abstract

Endobronchial photodynamic therapy for lung cancer

Abstract: PDT is an effective tool for the palliation of endobronchial lung cancers which obstruct the central airways and is also effective for the treatment of central microinvasive carcinoma and carcinoma in situ of the central airways.

Cited by 83 publications

References 53 publications

The Tyrosine Kinase Inhibitor Imatinib Mesylate Enhances the Efficacy of Photodynamic Therapy by Inhibiting ABCG2

The Tyrosine Kinase Inhibitor Imatinib Mesylate Enhances the Efficacy of Photodynamic Therapy by Inhibiting ABCG2

TRIM29 as a novel prostate basal cell marker for diagnosis of prostate cancer

Optical property measurements establish the feasibility of photodynamic therapy as a minimally invasive intervention for tumors of the kidney

Contact Info

Product

Resources

About